HOME >> BIOLOGY >> NEWS
Antimicrobial resistance poses increasing problem for growers

St. Paul, MN (August 23, 2001) An apple a day may keep the doctor away but apples themselves are often the victims of disease. In the past, growers have used antimicrobial compounds (or antibiotics as theyre more commonly known) to control fire blight, a common bacterial disease plaguing apples. But antimicrobial compounds are becoming less effective as microorganisms develop resistance to them. In fact, antimicrobial resistance is becoming an increasing problem for growers of other crops as well, and on August 29, the worlds largest group of plant health scientists will meet to discuss the problem of antimicrobial resistance in agriculture.

Antimicrobial agents play an important role in the control of plant diseases, both in the field and after harvesting states Paul Lewis, a plant health scientist, and organizer of the symposium planned for the end of August. Adds Lewis, Apples are a good example since antibiotics are critical for controlling fire blight disease and obtaining an acceptable harvest. However, apple and pear growers are really struggling with the effects of antibiotic resistance.

Since antimicrobial resistance has implications not only for the agricultural community, but the clinical and veterinary communities as well, Lewis has invited experts from these scientific disciplines to share their experience. He hopes their knowledge of the subject will provide new insights for plant disease scientists hoping to uncover alternative methods to fight diseases that are now being controlled with antimicrobial compounds. States Lewis, Its critical that we examine methods to prevent and/or manage antimicrobial resistance if we are to continue to receive the substantial benefits these agents offer. This symposium is designed to help us begin to do just that.


'"/>

Contact: Cindy Ash
cash@scisoc.org
651-454-7250
American Phytopathological Society
24-Aug-2001


Page: 1

Related biology news :

1. Antimicrobial peptides: new weapons to fight infection
2. Nabi reports successful reduction in S. aureus bacteremias at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
3. Antimicrobial Resistance: Issues And Options
4. Enzymes "Magic" May Hold Key to Anticancer and Antimicrobial Drugs
5. Master of antimalarial resistance
6. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
7. Evolvability could be a driving force in drug resistance
8. Insecticide resistance: A constraint on evolutionary change
9. New drug shows promise against Gleevec resistance in mice
10. New milestones on the path to conquering HIV drug resistance (AIDS)
11. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it

Post Your Comments:
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: